A carregar...
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regime...
Na minha lista:
| Publicado no: | Curr Opin Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams And Wilkins
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7015186/ https://ncbi.nlm.nih.gov/pubmed/31904664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000561 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|